AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Eduardo Bolsonaro Granted U.S. Green Card Amid Brazil Legal Battle and Tariff Dispute 
EEOC Drops Penn Subpoena in Antisemitism Probe, Investigation Continues 
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer 
Appeals Court Rejects Trump Bid to Reinstate $100,000 H-1B Visa Fee 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
DOJ Subpoenas New York Times Freelancer Over North Korea Military Report 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Civil Rights Groups Sue Trump Administration Over Childcare Funding Freeze and Influencer's Role 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
A California jury has awarded $40 million in damages to two women who claimed that long-term use of Johnson & Johnson’s talc-based baby powder caused their ovarian cancer, marking a significant development in the company’s ongoing talc litigation. The verdict was delivered Friday in Los Angeles Superior Court, where jurors concluded that Johnson & Johnson knew for decades about potential cancer risks associated with its baby powder products but failed to warn consumers.
The jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. Both women are California residents who testified that they used Johnson & Johnson baby powder daily after bathing for roughly 40 years. Kent was diagnosed with ovarian cancer in 2014, while Schultz received her diagnosis in 2018. According to trial testimony, both women underwent extensive medical treatment, including major surgeries and numerous rounds of chemotherapy.
During closing arguments, plaintiffs’ attorney Andy Birchfield told jurors that internal company knowledge about cancer risks linked to talc dated back to the 1960s. He argued that Johnson & Johnson deliberately concealed this information to protect sales. The jury ultimately agreed, finding the company liable for failing to warn consumers about potential dangers.
Johnson & Johnson has strongly denied the claims and announced plans to immediately appeal the verdict. Erik Haas, the company’s worldwide vice president of litigation, said the company expects to prevail, arguing that the decision represents an “aberrant adverse verdict.” Defense attorney Allison Brown told jurors that no major U.S. health authority has established a causal link between talc use and ovarian cancer, and that no scientific study proves talc can migrate to reproductive organs.
Johnson & Johnson is currently facing more than 67,000 lawsuits related to its talc products, the majority involving ovarian cancer claims. The company stopped selling talc-based baby powder in the United States in 2020, switching to a cornstarch alternative. Efforts to resolve the litigation through bankruptcy have been rejected multiple times by federal courts, allowing cases to resume.
The verdict underscores the ongoing legal and financial risks Johnson & Johnson faces as talc cancer lawsuits continue to move forward in courts across the country.
